Navigation Links
BioDelivery Sciences Announces $40 Million Registered Financing
Date:11/28/2012

RALEIGH, N.C., Nov. 28, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announces that it has received definitive commitments from institutional investors (including existing investors of the company) for an at market registered direct financing yielding gross proceeds of $40 million to BDSI. The financing is expected to close on December 3, 2012, subject to customary closing conditions. 

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

Under the terms of subscription agreements entered into with the investors, BDSI will sell an aggregate of 6,791,887 shares of its common stock at a price equal to $4.21 per share, and 2,709,300 shares of newly designated Series A Convertible Preferred Stock (Series A Preferred) at a price of $4.21 per share. The shares of common stock and Series A Preferred are being sold at the consolidated closing bid price of BDSI's common stock on November 27, 2012.

The Series A Preferred is being used in the financing as an accommodation to those investors who desire to not own in excess of 9.98% of BDSI's outstanding voting securities following the financing.  The Series A Preferred is non-voting and carries a liquidation preference of $0.001 per share. Each share of Series A Preferred is convertible into one share of BDSI's common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.98% of the total number of BDSI shares of common stock outstanding following conversion.  

Proceeds from this financing are expected to be used to fund completion of the Phase 3 clinical development program for BEMA Buprenorphine for chronic pain and progress BEMA Buprenorphine/Naloxone (BNX) for opioid dependence to the submissio
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
3. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
7. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
8. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
10. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- MHG Medical Management Services, a ... Medical Equipment and X-ray Annual Inspection & ... to the cruise industry,s unique requirements.  MHG Medical,s ... propose that they should develop a new service. ... intended to create standardized processes and raise standards, ...
(Date:7/29/2014)... July 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... report its second quarter 2014 financial results after the ... will then host a live conference call and webcast ... update Thursday morning, August 7, 2014 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1907 ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... NanoBio Corporation,announced today that it has seen ... 2 study of NB-002, a topical lotion for ... results clearly,justify completing the study, according to NanoBio ... grow out a clear nail after,successfully treating the ...
... March 20 PLC Systems Inc.,(Amex: PLC ... approval from,the U.S. Food and Drug Administration (FDA) ... study the effectiveness of the Company,s RenalGuard,Therapy(TM) and ... Mark R. Tauscher, President and Chief Executive ...
Cached Medicine Technology:NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 3PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 4
(Date:7/30/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... iFitDress.com, a well-known wedding dress manufacturer and retailer, has unveiled ... from this, it has announced that all of them are ... of its old and new clients may now access the ... “We are pleased to release the new collection of satin ... of amazing items. It is true that our satin bridal ...
(Date:7/29/2014)... 2014 Dignity Sciences Limited, a privately ... a Phase I trial with DS107G, an oral formulation ... was a randomized, placebo-controlled, double-blind, single-ascending and multiple dose ... and effect of food on DS107G in healthy subjects. ... of DGLA following both single and multiple oral doses ...
(Date:7/29/2014)... discovered a chemical alteration in a single human gene ... studies, could give doctors a simple blood test to ... The discovery, described online in The American Journal ... involved in the function of the brain,s response to ... might otherwise be an unremarkable reaction to the strain ...
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps ... that he cured his condition with the use of this ... of his experience. , He claimed that he was ... just 4 days. Since his method turned out being so ... around the world. , The Nasal Polyps Treatment Miracle ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2
... the US Food and Drug Administration gave its approval ... in the treatment of chronic Hepatitis B// (HBV). Clinical studies ... effects and is usually well tolerated. ,Hepatitis B ... 70,000 Americans every year. It is a serious illness and ...
... workplace cafeterias and vending machines, to understand the nature of ... in the levels of obesity, this is certainly called for, ... diseases. ,The Ministry of Health will keep ... next two years to ascertain the types of food enabled ...
... vaccine are underway in Mozambique, certainly not a farfetched goal ... The production// of the vaccine is estimated at about $60-million. ... addressing a gathering of health officials said 'We think the ... tests in Manhica (north of the capital Maputo) are effective. ...
... boy died of dengue fever here Wednesday, taking the toll ... as officials maintained that the number of cases had dropped ... Pradesh, died at the All India Institute of Medical Sciences ... in a critical condition. , ,"His condition was deteriorating ...
... light on the alarming trend among teenage girls taking to smoking//, ... to dispel the myth that smoking helps in controlling weight. , ... much the same way as their peers who do not smoke. ... which deserves to be puffed out. , ,Dr. Louise Pilote, ...
... dose of folic acid every day could have better chance of ... a form of vitamin B is used in our bodies to ... her body before she is pregnant, it can help prevent major ... latest study involving more than 18,000 women for the first time ...
Cached Medicine News:Health News:13-Year-Old Boy Is Latest Dengue Victim; Delhi Toll 47 2Health News:Folic Acid Supplements Could Help Conception 2
... utilizes allele-specific primer combinations in the PCR ... that only primers whose sequence is completely ... converted by the polymerase into PCR products. ... product. Using the Biotest SSP Kit Systems, ...
... The freezer is constructed with built-in bags ... the plasma bags are placed without contacting the ... and heavy inserts. This device ensures easy handling ... immersed plasma bags so that the relatively hot ...
Helmer offers Plasma Storage Freezer lines, the i.Series ipf 125-8. It is Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost tim...
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...
Medicine Products: